DIANA HAUSMAN
CIK 1563992 · Chief Medical Officer · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.92M
Companies
4
Total Filings
27
Lifetime Open-Market Net
-$3.21M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMRX | Director | 5,500 | $4.24 | $23.3K | $19.9K | 7 | 2026-06-11 |
| ZNTL | Chief Medical Officer | 373,876 | $4.62 | $1.73M | -$42.4K | 3 | 2024-05-09 |
| ZYME | Chief Medical Officer | 7,377 | $22.61 | $166.8K | -$3.22M | 10 | 2021-03-12 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Chief Medical Officer | 5,747 | — | — | $26.7K | 5 | 2015-09-28 |
Recent Filings · Page 2 of 3
27 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-23 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2022-01-18 | IMRX | Grant (A) | — | $0 | EDGAR |
| 2021-03-12 | ZYME | Mixed | +1,452 | -$36.6K | EDGAR |
| 2021-01-11 | ZYME | Grant (A) | +207 | $6.4K | EDGAR |
| 2020-12-04 | ZYME | Mixed | — | -$266.8K | EDGAR |
| 2020-12-03 | ZYME | Mixed | — | -$830.8K | EDGAR |
| 2020-09-16 | ZYME | Mixed | — | -$1.25M | EDGAR |
| 2020-07-06 | ZYME | Grant (A) | +367 | $11.3K | EDGAR |
| 2020-03-11 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2020-01-09 | ZYME | Grant (A) | +332 | $6.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.